Soluble TWEAK levels predict the presence of carotid atherosclerotic plaques in subjects free from clinical cardiovascular diseases

Atherosclerosis

Volumn 239, Issue 2, 2015, Pages 358-363

  Fernández Laso, Valvanera ^a   Sastre, Cristina ^a   Valdivielso, Jose M ^b   Fernández, Elvira ^b   Martín Ventura, Jose L ^a   Egido, Jesús ^a   Blanco Colio, Luis M ^a  

^a 28400 Madrid   (Spain)

^b HOSPITAL ARNAU DE VILANOVA   (Spain)

Author keywords

Asymptomatic subjects; Atherosclerosis; Biomarker; Carotid; STWEAK

Indexed keywords

SOLUBLE TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; TNFSF12 PROTEIN, HUMAN;

ADULT; AGED; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; ADOLESCENT; ATHEROSCLEROSIS; BLOOD; CAROTID ARTERY; CASE CONTROL STUDY; CLINICAL TRIAL; ECHOGRAPHY; FEMORAL ARTERY; GENE EXPRESSION REGULATION; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; QUESTIONNAIRE; RISK FACTOR;

ADOLESCENT; ADULT; AGED; ATHEROSCLEROSIS; BIOMARKERS; CAROTID ARTERIES; CAROTID INTIMA-MEDIA THICKNESS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; FEMORAL ARTERY; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; SURVEYS AND QUESTIONNAIRES; TUMOR NECROSIS FACTORS;

EID: 84922653488     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.01.040     Document Type: Article

References (36)

1. Winkles J.A. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat. Rev. Drug Discov. 2008, 7:411-425.
2. Munoz-Garcia B., Martin-Ventura J.L., Martinez E., Sanchez S., Hernandez G., Ortega L., Ortiz A., Egido J., Blanco-Colio L.M. Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: modulation by atorvastatin. Stroke 2006, 37:2044-2053.
3. Muñoz-García B., Moreno J.A., López-Franco O., Sanz A.B., Martín-Ventura J.L., Blanco J., Jakubowski A., Burkly L.C., Ortiz A., Egido J., Blanco-Colio L.M. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) enhances vascular and renal damage induced by hyperlipidemic diet in ApoE-knockout mice. Arterioscler. Thromb. Vasc. Biol. 2009, 29:2061-2068.
4. Schapira K., Burkly L.C., Zheng T.S., Wu P., Groeneweg M., Rousch M., Kockx M.M., Daemen M.J., Heeneman S. Fn14-Fc fusion protein regulates atherosclerosis in ApoE-/- mice and inhibits macrophage lipid uptake invitro. Arterioscler. Thromb. Vasc. Biol. 2009, 29:2021-2027.
5. Sastre C., Fernández-Laso V., Madrigal-Matute J., Muñoz-García B., Moreno J.A., Pastor-Vargas C., Llamas-Granda P., Burkly L.C., Egido J., Martín-Ventura J.L., Blanco-Colio L.M. Genetic deletion or TWEAK blocking antibody administration reduce atherosclerosis and enhance plaque stability in mice. J.Cell. Mol. Med. 2014, 18:721-734.
6. Tarín C., Fernández-Laso V., Sastre C., Madrigal-Matute J., Gómez M., Zaragoza C., Egido J., Burkly L.C., Martín-Ventura J.L., Blanco-Colio L.M. Tumor necrosis factor-like weak inducer of apoptosis or Fn14 deficiency reduce elastase perfusion-induced aortic abdominal aneurysm in mice. J.Am. Heart Assoc. 2014, 3:e000723.
7. Potrovita I., Zhang W., Burkly L., Hahm K., Lincecum J., Wang M.Z., Maurer M.H., Rossner M., Schneider A., Schwaninger M. Tumor necrosis factor-like weak inducer of apoptosis-induced neurodegeneration. J.Neurosci. 2004, 24:8237-8244.
8. Jain M., Jakubowski A., Cui L., Shi J., Su L., Bauer M., Guan J., Lim C.C., Naito Y., Thompson J.S., Sam F., Ambrose C., Parr M., Crowell T., Lincecum J.M., Wang M.Z., Hsu Y.M., Zheng T.S., Michaelson J.S., Liao R., Burkly L.C. Anovel role for tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in the development of cardiac dysfunction and failure. Circulation 2009, 119:2058-2068.
9. Pachel C., Mathes D., Bayer B., Dienesch C., Wangorsch G., Heitzmann W., Lang I., Ardehali H., Ertl G., Dandekar T., Wajant H., Frantz S. Exogenous administration of a recombinant variant of TWEAK impairs healing after myocardial infarction by aggravation of inflammation. PLoS One 2013, 8:e78938.
10. Chicheportiche Y., Bourdon P.R., Xu H., Hsu Y.M., Scott H., Hession C., Garcia I., Browning J.L. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J.Biol. Chem. 1997, 272:32401-32410.
11. Blanco-Colio L.M., Martín-Ventura J.L., Muñóz-García B., Orbe J., Páramo J.A., Michel J.B., Ortiz A., Meilhac O., Egido J. Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2007, 27:916-922.
12. Kralisch S., Ziegelmeier M., Bachmann A., Seeger J., Lössner U., Blüher M., Stumvoll M., Fasshauer M. Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease. Atherosclerosis 2008, 199:440-444.
13. Jelić-Ivanović Z., Bujisić N., Spasić S., Bogavac-Stanojević N., Spasojević-Kalimanovska V., Kotur-Stevuljević J. Circulating sTWEAK improves the prediction of coronary artery disease. Clin. Biochem. 2009, 42:1381-1386.
14. Chorianopoulos E., Rosenberg M., Zugck C., Wolf J., Katus H.A., Frey N. Decreased soluble TWEAK levels predict an adverse prognosis in patients with chronic stable heart failure. Eur. J. Heart Fail 2009, 11:1050-1056.
15. Martín-Ventura J.L., Lindholt J.S., Moreno J.A., Vega de Céniga M., Meilhac O., Michel J.B., Egido J., Blanco-Colio L.M. Soluble TWEAK plasma levels predict expansion of human abdominal aortic aneurysms. Atherosclerosis 2011, 214:486-489.
16. Moreno J.A., Dejouvencel T., Labreuche J., Smadja D.M., Dussiot M., Martin-Ventura J.L., Egido J., Gaussem P., Emmerich J., Michel J.B., Blanco-Colio L.M., Meilhac O. Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio. Arterioscler. Thromb. Vasc. Biol. 2010, 30:1253-1262.
17. Yilmaz M.I., Sonmez A., Ortiz A., Saglam M., Kilic S., Eyileten T., Caglar K., Oguz Y., Vural A., Çakar M., Egido J., Altun B., Yenicesu M., Blanco-Colio L.M., Carrero J.J. Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes. Clin. J. Am. Soc. Nephrol. 2011, 6:785-792.
18. Hassan S.B., El-demery A.B., Ahmed A.I., Abukhalil R.E. Soluble TWEAK and cardiovascular morbidity and mortality in chronic kidney disease patients. Arab. J. Nephrol. Transpl. 2012, 5:27-32.
19. Valdivielso J.M., Coll B., Martín-Ventura J.L., Moreno J.A., Egido J., Fernández E., Blanco-Colio L.M. Soluble TWEAK is associated with atherosclerotic burden in patients with chronic kidney disease. J.Nephrol. 2013, 26:1105-1113.
20. Turkmen K., Tonbul H.Z., Erdur F.M., Toker A., Biyik Z., Ozbiner H., Gaipov A., Gul E.E., Kayrak M., Solak Y., Ozbek O., Turk S., Covic A. Soluble TWEAK independently predicts atherosclerosis in renal transplant patients. BMC Nephrol. 2013, 14:144.
21. Gungor O., Kismali E., Sisman A.R., Kircelli F., Carrero J.J., Tatar E., Asci G., Toz H. The relationships between serum sTWEAK, FGF-23 levels, and carotid atherosclerosis in renal transplant patients. Ren. Fail 2013, 35:77-81.
22. Yilmaz M.I., Carrero J.J., Ortiz A., Martín-Ventura J.L., Sonmez A., Saglam M., Yaman H., Yenicesu M., Egido J., Blanco-Colio L.M. Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2009, 4:1716-1723.
23. Yilmaz M.I., Sonmez A., Saglam M., Yaman H., Unal H.U., Gok M., Cetinkaya H., Eyileten T., Oguz Y., Sari S., Yildirim A.O., Vural A., Carrero J.J., Blanco-Colio L.M. Soluble TWEAK plasma levels increase after renal transplantation and associate with the improvement of endothelial function. Eur. J. Clin. Invest 2013, 43:1250-1257.
24. Junyent M., Martínez M., Borràs M., Coll B., Valdivielso J.M., Vidal T., Sarró F., Roig J., Craver L., Fernández E. Predicting cardiovascular disease morbidity and mortality in chronic kidney disease in Spain. The rationale and design of NEFRONA: a prospective, multicenter, observational cohort study. BMC Nephrol. 2010, 11:14.
25. Stein J.H., Korcarz C.E., Hurst R.T., Lonn E., Kendall C.B., Mohler E.R., Najjar S.S., Rembold C.M., Post W.S., American Society of Echocardiography Carotid Intima-Media Thickness Task Force Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensos statement from the American society of echocardiography carotid intima-media thickness task force endorsed by the society for vascular medicine. J.Am. Soc. Echocardiogr. 2008, 21:93-111.
26. Touboul P.J., Hennerici G., Meairs S., Adams H., Amarenco P., Desvarieux M., Ebrahim S., Fatar M., Hernandez Hernandez R., Kownator S., Prati P., Rundek T., Taylor A., Bornstein N., Csiba L., Vicaut E., Woo K.S., Zannad F., Advisory Board of the 3rd Watching the Risk Symposium 2004, 13th European Stroke Conference Mannheim intima-media thickness consensus. Cerebrovasc. Dis. 2004, 18:346-349.
27. Nambi V., Chambless L., Folsom A.R., He M., Hu Y., Mosley T., Volcik K., Boerwinkle E., Ballantyne C.M. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk the ARIC (Atherosclerosis Risk in Communities) study. J.Am. Coll. Cardiol. 2010, 55:1600-1607.
28. Polak J.F., Pencina M.J., Pencina K.M., O'Donnell C.J., Wolf P.A., D'Agostino R.B. Carotid-wall intima-media thickness and cardiovascular events. N.Engl. J. Med. 2011, 365:213-221.
29. Llauradó G., González-Clemente J.M., Maymó-Masip E., Subías D., Vendrell J., Chacón M.R. Serum levels of TWEAK and scavenger receptor CD163 in type 1 diabetes mellitus: relationship with cardiovascular risk factors. a case-control study. PLoS One 2012, 7:e43919.
30. Karadurmus N., Tapan S., Cakar M., Naharci I., Celik T., Tasci I., Sayin S., Dogan T., Turker T., Erbil M.K., Saglam K. Lower plasma soluble TWEAK concentration in patients with newly diagnosed hypertension. Clin. Invest Med. 2012, 35:E20-E26.
31. Chorianopoulos E., Jarr K., Steen H., Giannitsis E., Frey N., Katus H.A. Soluble TWEAK is markedly upregulated in patients with ST-elevation myocardial infarction and related to an adverse short-term outcome. Atherosclerosis 2010, 211:322-326.
32. Herisson F., Heymann M.F., Chétiveaux M., Charrier C., Battaglia S., Pilet P., Rouillon T., Krempf M., Lemarchand P., Heymann D., Gouëffic Y. Carotid and femoral atherosclerotic plaques show different morphology. Atherosclerosis 2011, 216:348-354.
33. Moreno J.A., Muñoz-García B., Martín-Ventura J.L., Madrigal-Matute J., Orbe J., Páramo J.A., Ortega L., Egido J., Blanco-Colio L.M. The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Atherosclerosis 2009, 207:103-110.
34. Harada N., Nakayama M., Nakano H., Fukuchi Y., Yagita H., Okumura K. Pro-inflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun. 2002, 299:488-493.
35. Blanco-Colio L.M., Martín-Ventura J.L., Carrero J.J., Yilmaz M.I., Moreno J.A., Gómez-Guerrero C., Ortiz A., Egido J. Vascular proteomics and the discovery process of clinical biomarkers: the case of TWEAK. Proteomics Clin. Appl. 2011, 5:281-288.
36. Bertin D., Stephan D., Khrestchatisky M., Desplat-Jégo S. Is TWEAK a biomarker for Autoimmune/Chronic inflammatory diseases?. Front. Immunol. 2013 Dec 27, 4:489.